渤健(BIIB)和日本卫材用于治疗阿尔茨海默症的家庭版疗法获得美国食品药品管理局(FDA)批准。Leqembi Iqlik是一种自动注射类药物在接受18个月的初步治疗之后病患可以在有旁人监督的情况下于家里使用。该产品计划10月6日在美国市场推出。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.